Dr. Rapoport on Rolapitant for the Prevention of CINV

Video

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

This phase III trial, of which the results were presented at the 2014 MASCC/ISOO International Symposium, analyzed 555 cisplatin-naïve subjects treated with highly emetogenic chemotherapy (≥60mg/m2 cisplatin). Patients were randomized to receive rolapitant, granisetron, and dexamethasone, or placebo, granisetron, and dexamethasone.

Rolapitant is different from other NK-1 inhibitors in that it does not interaction with any other drug and has a long half-life.

In this trial, rolapitant demonstrated superior efficacy in the primary endpoint of delayed CINV in this population.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,